Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Antithrombotic therapy could be related with nuisance bleeding. This study investigated whether vitreous hemorrhage(VH) is associated with specific types of antithrombotic medication in patients with atrial fibrillation (AF). Materials and Methods: In the Korean National Health Insurance Service National Sample Cohort, we identified 9352 antiplatelet/anticoagulant-treated AF patients. The occurrence of VH was compared between warfarin (n=1493) and a propensity score (PS)-matched antiplatelet group (n=1493) and between warfarin (n=1493) and a PS-matched warfarin+antiplatelet group (n=1493). Results: The outcomes of VH were lower in the warfarin than in the matched antiplatelet (1.45 vs. 3.72 events/1000 patient-years)and matched warfarin+antiplatelet groups (1.45 vs. 6.87 events/1000 patient-years). Compared with warfarin, the risk of VH increasedwith antiplatelet [adjusted hazard ratio (aHR) 3.90; 95% confidence interval (CI) 1.22–12.4, p=0.022] and warfarin+antiplateletagents (aHR 4.39, 95% CI 1.74–11.2, p=0.002). Compared with warfarin only, warfarin+antiplatelet agents increased the risk of VHin patients ≥65 years, regardless of gender and hypertension. The risk of VH was significantly higher with dual antiplatelet therapy(aHR: 5.02, 95% CI: 1.56–16.2, p=0.007) or in dual (aHR: 5.02, 95% CI: 1.74–14.5, p=0.003) or triple therapy using warfarin and antiplateletagents than with warfarin monotherapy (aHR: 6.12, 95% CI: 1.76–21.3, p=0.004). Conclusion: Dual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy. Consideringthe low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplateletagents should be avoided to prevent VH in AF patients.
Abstract
Purpose: Antithrombotic therapy could be related with nuisance bleeding. This study investigated whether vitreous hemorrhage(VH) is associated with specific types of antithrombotic medication in patients with atrial fibrillation (AF). Materials and Methods: In the Korean National Health Insurance Service National Sample Cohort, we identified 9352 antiplatelet/anticoagulant-treated AF patients. The occurrence of VH was compared between warfarin (n=1493) and a propensity score (PS)-matched antiplatelet group (n=1493) and between warfarin (n=1493) and a PS-matched warfarin+antiplatelet group (n=1493). Results: The outcomes of VH were lower in the warfarin than in the matched antiplatelet (1.45 vs. 3.72 events/1000 patient-years)and matched warfarin+antiplatelet groups (1.45 vs. 6.87 events/1000 patient-years). Compared with warfarin, the risk of VH increasedwith antiplatelet [adjusted hazard ratio (aHR) 3.90; 95% confidence interval (CI) 1.22–12.4, p=0.022] and warfarin+antiplateletagents (aHR 4.39, 95% CI 1.74–11.2, p=0.002). Compared with warfarin only, warfarin+antiplatelet agents increased the risk of VHin patients ≥65 years, regardless of gender and hypertension. The risk of VH was significantly higher with dual antiplatelet therapy(aHR: 5.02, 95% CI: 1.56–16.2, p=0.007) or in dual (aHR: 5.02, 95% CI: 1.74–14.5, p=0.003) or triple therapy using warfarin and antiplateletagents than with warfarin monotherapy (aHR: 6.12, 95% CI: 1.76–21.3, p=0.004). Conclusion: Dual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy. Consideringthe low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplateletagents should be avoided to prevent VH in AF patients.
참고문헌 (35)
- Kim D, "10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population", Am Heart J, 202, pp.20~26 (2018)
- Kim D, "Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006through 2015", Heart, 104, pp.2010~2017 (2018)
- , vascular disease, age 65-74, female)for stroke in Asian patients with atrial fibrillation : a Korean nationwide sample cohort study, "Stroke", 2017, 1524~1530
- Yang PS, "Variations of prevalence and incidence of atrial fibrillation and oral anticoagulation rate according to different analysis approaches", Sci Rep, 8, pp.6856~ (2018)
- O’Brien EC, "Prognostic significance of nuisance bleeding in anticoagulated patients with atrial fibrillation", Circulation, 138, pp.889~897 (2018)
- Kiernan DF, "Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration", Retina, 30, pp.1573~1578 (2010)
- Witmer MT, "Oral anticoagulation and the risk of vitreous hemorrhage and retinal tears in eyes with acute posterior vitreous detachment", Retina, 33, pp.621~626 (2013)
- Biyik I, "Ocular bleeding related to warfarin anticoagulation in patients with mechanical heart valve and atrial fibrillation", J Int Med Res, 35, pp.143~149 (2007)
- Brown JS, "Anticoagulation and clinically significant postoperative vitreous hemorrhage in diabetic vitrectomy", Retina, 31, pp.1983~1987 (2011)
- Olson JM, "Association between systemic anticoagulation and rate of intraocular hemorrhage following intravitreal anti-VEGF therapy for age-related macular degeneration", Ophthalmic Surg Lasers Imaging Retina, 44, pp.455~459 (2013)
- Benzimra JD, "The Cataract National Dataset electronic multicentre audit of 55,567 operations: antiplatelet and anticoagulant medications", Eye (Lond), 23, pp.10~16 (2009)
- Katz J, "Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery", Ophthalmology, 110, pp.1784~1788 (2003)
- Lee J, "Cohort Profile : The National Health Insurance Service-National Sample Cohort(NHISNSC), South Korea", Int J Epidemiol, 46, pp.e15~ (2017)
- 이한철, "The Trends of Atrial Fibrillation-Related Hospital Visit and Cost, Treatment Pattern and Mortality in Korea: 10-Year Nationwide Sample Cohort Data", Korean Circulation Journal, 47(1), pp.56~64 (2017), 대한심장학회
- Baek YS, "Associations of abdominal obesity and new-onset atrial fibrillation in the general population", J Am Heart Assoc, 6, pp.e004705~ (2017)
- Lee HY, "Atrial fibrillation and the risk of myocardial infarction : a nation-wide propensity-matched study", Sci Rep, 7, pp.12716~ (2017)
- Song S, "Relation of chronic obstructive pulmonary disease to cardiovascular disease in the general population", Am J Cardiol, 120, pp.1399~1404 (2017)
- Sahai H, "Statistics in epidemiology: methods, techniques, and applications" (1996), CRC Press
- Hart RG, "Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)
- Ogilvie IM, "Underuse of oral anticoagulants in atrial fibrillation : a systematic review", Am J Med, 123, pp.638~645 (2010)
- 김형수, "A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry", Korean Circulation Journal, 47(6), pp.877~887 (2017), 대한심장학회[DOI]
- O’Brien EC, "Reasons for warfarin discontinuation in the outcomes registry for better informed treatment of atrial fibrillation(ORBITAF)", Am Heart J, 168, pp.487~494 (2014)
- Gumbinger C, "Reasons underlying non-adherence to and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation", Eur Neurol, 73, pp.184~191 (2015)
- Altman R, "Bleeding tendency in dual antiplatelet therapy with aspirin", clopidogrel : rescue of the template bleeding time in a single-center prospective study, 2012, pp.10, 3~
- Rosenman MB, "Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records", Curr Med Res Opin, 28, pp.1407~1414 (2012)
- Lindgren G, "A prospective study of dense spontaneous vitreous hemorrhage", Am J Ophthalmol, 119, pp.458~465 (1995)
- Oh J, "Antiplatelet and anticoagulation therapy in vitreoretinal surgery", Am J Ophthalmol, 151, pp.934~939 (2011)
- Dewilde WJ, "Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : an open-label, randomised, controlled trial", Lancet, 381, pp.1107~1115 (2013)
- Rubboli A, "The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th anniversary overview", Thromb Haemost, 112, pp.1080~1087 (2014)
- Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation", N Engl J Med, 377, pp.1513~1524 (2017)
- Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI", N Engl J Med, 375, pp.2423~2434 (2016)
- Golwala HB, "Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials", Eur Heart J, 39, pp.1726~1735 (2018)
- Kuhli-Hattenbach C, "Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy", Am J Ophthalmol, 149, pp.316~321 (2010)
- Ying GS, "Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the comparison of age-related macular degeneration treatments trials", Ophthalmology, 123, pp.352~360 (2016)
- Moon SW, "Incidence and risk factors for macular hemorrhage following intravitreal ranibizumab injection for neovascular age-related macular degeneration", J Ocul Pharmacol Ther, 29, pp.556~559 (2013)